Stock Events

Stock Events

Novartis 

€145.00
2382
+€1.00+0.69%Friday 19:03

Statistics

Day High
146
Day Low
141
52W High
147
52W Low
107
Volume
1
Avg. Volume
-
Mkt Cap
273.85B
P/E Ratio
32.15
Dividend Yield
2.84%
Dividend
4.12

Upcoming

Dividends

2.84%Dividend Yield
Mar 2026
€4.12
Apr 2025
€3.51
Apr 2024
€3.51
Mar 2023
€3.26
Mar 2022
€3.00
10Y Growth
5.52%
5Y Growth
8.98%
3Y Growth
8.1%
1Y Growth
17.33%

Earnings

Feb 3Expected
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Next
1.68
1.86
2.04
2.21
Expected EPS
2.0124257817999998
Actual EPS
N/A

Financials

24.72%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
49.19BRevenue
12.16BNet Income

Analyst Ratings

$103.20Average Price Target
The highest estimate is ⁦103.20⁩.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
50%
Sell
50%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NOTA.STU. It's not an investment recommendation.
Microsoft
391
MSFT
Coca-Cola
364
KO
Apple
335
AAPL
Realty Income
329
O

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Pfizer
PFE
Mkt Cap173.95B
Pfizer competes directly with Novartis in various therapeutic areas, including cardiovascular, oncology, and immunology.
Johnson & Johnson
JNJ
Mkt Cap657.68B
Johnson & Johnson, through its pharmaceutical segment, competes in areas such as immunology and oncology, similar to Novartis.
Merck
MRK
Mkt Cap368.89B
Merck is a key competitor in the oncology sector, directly competing with Novartis' cancer treatments.
Roche
RHHBY
Mkt Cap334.28B
Roche competes closely with Novartis, especially in oncology and ophthalmology, with both companies headquartered in Switzerland.
Abbvie
ABBV
Mkt Cap521.11B
AbbVie competes in the immunology and oncology markets, areas where Novartis has significant investments.
GSK
GSK
Mkt Cap99.19B
GlaxoSmithKline competes with Novartis in respiratory, vaccines, and HIV, areas where Novartis has presence or interest.
Bristol-Myers Squibb
BMY
Mkt Cap127.71B
Bristol Myers Squibb is a competitor in the oncology and cardiovascular markets, directly competing with Novartis' drug portfolio.
Sanofi
SNY
Mkt Cap106.24B
Sanofi competes with Novartis in areas such as vaccines, oncology, and cardiovascular diseases.
Astrazeneca
AZN
Mkt Cap289.48B
AstraZeneca competes in the oncology, cardiovascular, and respiratory sectors, overlapping with Novartis' interests.
AMGEN
AMGN
Mkt Cap251.94B
Amgen competes with Novartis in the biopharmaceutical sector, particularly in treatments for bone diseases, cancer, and cardiovascular diseases.

About

Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
Show More
CEO
Vasant Narasimhan
Employees
75267
Country
Switzerland
ISIN
US66987V1098
WKN
000907122

Listings

MX
MX
NOVNN.MX
NEO
CA
NOVN.NEO
STU
DE
NOT.STU
F
DE
NOT0.F

0 Comments

Share your thoughts

FAQs

What is Novartis stock price today?▼
The current price of NOTA.STU is €145.00 EUR — it has increased by +0.69% in the past 24 hours. Watch Novartis stock price performance more closely on the chart.
What is Novartis stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Novartis stocks are traded under the ticker NOTA.STU.
Is Novartis stock price growing?▼
NOTA.STU stock has risen by +1.4% compared to the previous week, the month change is a +14.17% rise, over the last year Novartis has showed a +33.64% increase.
What is Novartis market cap?▼
Today Novartis has the market capitalization of 273.85B
When is the next Novartis earnings date?▼
Novartis is going to release the next earnings report on February 3, 2027.
What were Novartis earnings last quarter?▼
NOTA.STU earnings for the last quarter are 2.21 EUR per share, whereas the estimation was 2.04 EUR resulting in a +8.28% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Novartis revenue for the last year?▼
Novartis revenue for the last year amounts to 49.19B EUR.
What is Novartis net income for the last year?▼
NOTA.STU net income for the last year is 12.16B EUR.
Does Novartis pay dividends?▼
Yes, NOTA.STU dividends are paid annual. The last dividend per share was 4.12 . As of today, Dividend Yield (FWD)% is 2.84%.
How many employees does Novartis have?▼
As of November 7, 2026, the company has 75,267 employees.
In which sector is Novartis located?▼
Novartis operates in the Health & Wellness sector.
When did Novartis complete a stock split?▼
Novartis has not had any recent stock splits.
Where is Novartis headquartered?▼
Novartis is headquartered in Basel, Switzerland.